Novartis AG (MEX:NOVNN) Cyclically Adjusted FCF per Share: MXN105.92 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NOVNN Novartis AG MEX:NOVNN
69 GF Score
Price MXN2,753.91
GF Value MXN2,293.62
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Cyclically Adjusted FCF per Share?

Novartis AG MEX:NOVNN 69 Cyclically Adjusted FCF per Share is MXN105.92 as of Jun. 2026. GuruFocus rates MEX:NOVNN with a GF Score™ of 69/100 and a GF Value™ of MXN2,293.62 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Novartis AG's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN46.713. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN105.92 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Novartis AG's average Cyclically Adjusted FCF Growth Rate was 5.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.80% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 4.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Novartis AG was 4.80% per year. The lowest was 0.50% per year. And the median was 1.80% per year.

As of today (2026-08-01), Novartis AG's current stock price is MXN2753.91. Novartis AG's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN105.92. Novartis AG's Cyclically Adjusted Price-to-FCF of today is 26.00.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novartis AG was 25.44. The lowest was 15.04. And the median was 18.34.


Novartis AG  (MEX:NOVNN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Novartis AG's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2753.91/105.92
=26.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Novartis AG was 25.44. The lowest was 15.04. And the median was 18.34.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Novartis AG Cyclically Adjusted FCF per Share Related Terms


Novartis AG Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted FCF per Share Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 93.47 89.33 122.51 114.14

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117.76 118.33 114.14 119.86 105.92

MEX:NOVNN vs LLY, JNJ, ABBV: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted Price-to-FCF falls into.


MEX:NOVNN
69GF Score
Novartis AG MEX:NOVNN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Novartis AG's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=46.713/108.5400*108.5400
=46.713

Current CPI (Jun. 2026) = 108.5400.

Novartis AG Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 18.603 99.604 20.272
201612 24.200 99.380 26.431
201703 11.751 100.040 12.749
201706 23.073 100.285 24.972
201709 22.441 100.254 24.296
201712 24.060 100.213 26.059
201803 14.243 100.836 15.331
201806 28.972 101.435 31.001
201809 25.673 101.246 27.523
201812 26.135 100.906 28.112
201903 14.870 101.571 15.890
201906 21.992 102.044 23.392
201909 34.353 101.396 36.773
201912 23.741 101.063 25.497
202003 20.921 101.048 22.472
202006 35.154 100.743 37.875
202009 24.269 100.585 26.188
202012 25.971 100.241 28.121
202103 11.479 100.800 12.360
202106 31.164 101.352 33.374
202109 40.011 101.533 42.772
202112 30.194 101.776 32.201
202203 7.032 103.205 7.396
202206 28.862 104.783 29.897
202209 39.206 104.835 40.592
202212 32.641 104.666 33.849
202303 21.834 106.245 22.306
202306 21.915 106.576 22.319
202309 39.413 106.570 40.142
202312 14.437 106.461 14.719
202403 8.952 107.355 9.051
202406 37.133 107.991 37.322
202409 53.301 107.468 53.833
202412 31.803 107.128 32.222
202503 22.236 107.722 22.405
202506 58.659 108.075 58.911
202509 54.276 107.710 54.694
202512 11.592 107.200 11.737
202603 27.002 108.060 27.122
202606 46.713 108.540 46.713

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN105.92 mean?
Novartis AG (MEX:NOVNN) has a Cyclically Adjusted FCF per Share of MXN105.92 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Novartis AG and its competitors.
Is Novartis AG's Cyclically Adjusted FCF per Share too high?
Novartis AG's current Cyclically Adjusted FCF per Share is MXN105.92. Overall, Novartis AG has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Cyclically Adjusted FCF per Share compare to LLY and JNJ?
Novartis AG's Cyclically Adjusted FCF per Share of MXN105.92 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Novartis AG and its competitors. Novartis AG's current Cyclically Adjusted FCF per Share is MXN105.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (MEX:NOVNN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,293.62, compared to a current price of MXN2,753.91 — trading 20.1% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN105.92. Novartis AG's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Novartis AG (MEX:NOVNN), the current Cyclically Adjusted FCF per Share is MXN105.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (MEX:NOVNN) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of MXN2,753.91 is trading 20.1% above its estimated GF Value™ of MXN2,293.62. GuruFocus considers Novartis AG to be Significantly Overvalued.

Key valuation signals for MEX:NOVNN:

  • Cyclically Adjusted FCF per Share: MXN105.92
  • GF Value™: MXN2,293.62 vs. price of MXN2,753.91 (20.1% above fair value)
  • GF Score™: 69/100 with 7 warning signs

No single metric tells the full story. See the MEX:NOVNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
69GF Score

Get the complete analysis for MEX:NOVNN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,753.91
Price
MXN2,293.62
GF Value